Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 699 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Embracing Lung Cancer Survivorship August 3, 2021 Why Wearing Comfortable Clothes During Cancer Treatment Matters October 21, 2021 Study Suggests Watching Disney Movies May Improve Quality of Life for... May 26, 2020 Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... April 13, 2021 Load more HOT NEWS To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated...
